Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 7
2012 6
2013 5
2014 9
2015 10
2016 13
2017 26
2018 39
2019 39
2020 64
2021 74
2022 71
2023 85
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Results by year

Filters applied: . Clear all
Page 1
Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus.
Denicolò S, Reinstadler V, Keller F, Thöni S, Eder S, Heerspink HJL, Rosivall L, Wiecek A, Mark PB, Perco P, Leierer J, Kronbichler A, Oberacher H, Mayer G. Denicolò S, et al. Among authors: heerspink hjl. Diabetologia. 2024 Apr 22. doi: 10.1007/s00125-024-06149-w. Online ahead of print. Diabetologia. 2024. PMID: 38647650
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials.
Fletcher RA, Herrington WG, Agarwal R, Mayne KJ, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Staplin N, Wheeler DC, Chertow GM, Heerspink HJL, Neuen BL. Fletcher RA, et al. Among authors: heerspink hjl. Clin J Am Soc Nephrol. 2024 Apr 16. doi: 10.2215/CJN.0000000000000470. Online ahead of print. Clin J Am Soc Nephrol. 2024. PMID: 38622766 No abstract available.
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, Herrington WG, Inzucchi SE, Jardine MJ, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Solomon SD, Staplin N, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Zhao Y, Heerspink HJL, Sabatine MS, Wiviott SD. Patel SM, et al. Among authors: heerspink hjl. Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069568. Online ahead of print. Circulation. 2024. PMID: 38583093 Free article.
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial.
Zhang Z, Heerspink HJL, Chertow GM, Correa-Rotter R, Gasparrini A, Jongs N, Langkilde AM, McMurray JJV, Mistry MN, Rossing P, Toto RD, Vart P, Nitsch D, Wheeler DC, Caplin B. Zhang Z, et al. Among authors: heerspink hjl. Lancet Planet Health. 2024 Apr;8(4):e225-e233. doi: 10.1016/S2542-5196(24)00026-3. Lancet Planet Health. 2024. PMID: 38580424 Free article. Clinical Trial.
Combination therapy for kidney disease in people with diabetes mellitus.
van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, Persson F, Rosas SE, Rossing P, Schaub JA, Tuttle K, Waikar SS, Heerspink HJL. van Raalte DH, et al. Among authors: heerspink hjl. Nat Rev Nephrol. 2024 Apr 3. doi: 10.1038/s41581-024-00827-z. Online ahead of print. Nat Rev Nephrol. 2024. PMID: 38570632 Review.
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
Schnell O, Barnard-Kelly K, Battelino T, Ceriello A, Larsson HE, Fernández-Fernández B, Forst T, Frias JP, Gavin JR 3rd, Giorgino F, Groop PH, Heerspink HJL, Herzig S, Hummel M, Huntley G, Ibrahim M, Itzhak B, Jacob S, Ji L, Kosiborod M, Lalic N, Macieira S, Malik RA, Mankovsky B, Marx N, Mathieu C, Müller TD, Ray K, Rodbard HW, Rossing P, Rydén L, Schumm-Draeger PM, Schwarz P, Škrha J, Snoek F, Tacke F, Taylor B, Jeppesen BT, Tesfaye S, Topsever P, Vilsbøll T, Yu X, Standl E. Schnell O, et al. Among authors: heerspink hjl. Cardiovasc Diabetol. 2024 Mar 19;23(1):104. doi: 10.1186/s12933-024-02180-8. Cardiovasc Diabetol. 2024. PMID: 38504284 Free PMC article.
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, Tuttle KR, Hadjadj S, Rossing P. Bornstein SR, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15518. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38497241
419 results